You are here


Nitroxyl (HNO) Releasing Therapeutics

The National Cancer Institute's Cancer and Inflammation Program is seeking statements of capability or interest from parties interested in licensing therapeutic agents that generate Nitroxyl (HNO) in physiological media.
NIH Reference Number
Product Type
  • nitroxyl
  • HNO
Collaboration Opportunity
This invention is available for licensing.
Description of Technology

Nitroxyl (HNO) has recently emerged as a prospective pharmacological agent.  Studies of the chemistry of HNO have led to an understanding that HNO is vastly different from nitric oxide (NO). HNO displays unique cardiovascular properties and has been shown to have positive effects in failing hearts without changing heart rate, and also has been shown to have beneficial effects in ischemia reperfusion injury.  In addition to the observed cardiovascular effects, HNO has shown initial promise in the realm of cancer therapy. HNO has been demonstrated to inhibit a key glycolytic enzyme. Due to the Warburg effect, inhibiting glycolysis is an attractive target for inhibiting tumor proliferation. HNO has recently been shown to inhibit tumor proliferation in mouse xenografts. Additionally, HNO inhibits tumor angiogenesis and induces cancer cell apoptosis.

The National Cancer Institute's Cancer and Inflammation Program discovered HNO releasing compounds and methods of treating various diseases with such compounds.

Potential Commercial Applications
  • Potential treatment for cardiovascular disease, ischemia, and cancer.
  • Tool to probe the role of HNO in normal physiology and disease states.
Competitive Advantages
  • Alleviated toxicity associated with chronic NSAID use
  • Controlled release of HNO

David A Wink (NCI), Larry K Keefer (NCI)

Development Stage

Switzer C et al. The emergence on nitroxyl (HNO) as a pharmacological agent. [PMID 19426703]

Keefer, LK.  Nitric oxide (NO)- and nitroxyl (HNO)-generating diazeniumdiolates (NONOates): emerging commercial opportunities. [PMID 16101424]

Patent Status
  • U.S. Patent Filed: U.S. Patent Application Number 61/315,604, Filed 19 Mar 2010
Therapeutic Area
Thursday, June 10, 2021